300 related articles for article (PubMed ID: 37452103)
41. Human aging DNA methylation signatures are conserved but accelerated in cultured fibroblasts.
Sturm G; Cardenas A; Bind MA; Horvath S; Wang S; Wang Y; Hägg S; Hirano M; Picard M
Epigenetics; 2019 Oct; 14(10):961-976. PubMed ID: 31156022
[TBL] [Abstract][Full Text] [Related]
42. Novel xeno-free and serum-free culturing condition to improve piggyBac transposon-based CD19 chimeric antigen receptor T-cell production and characteristics.
Sanyanusin M; Tudsamran S; Thaiwong R; Tawinwung S; Nishio N; Takahashi Y; Hirankarn N; Suppipat K
Cytotherapy; 2023 Apr; 25(4):397-406. PubMed ID: 36517366
[TBL] [Abstract][Full Text] [Related]
43. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
44. Epigenetic engineering for optimal chimeric antigen receptor T cell therapy.
Ito Y; Kagoya Y
Cancer Sci; 2022 Nov; 113(11):3664-3671. PubMed ID: 36000807
[TBL] [Abstract][Full Text] [Related]
45. Reducing
Ghassemi S; Nunez-Cruz S; O'Connor RS; Fraietta JA; Patel PR; Scholler J; Barrett DM; Lundh SM; Davis MM; Bedoya F; Zhang C; Leferovich J; Lacey SF; Levine BL; Grupp SA; June CH; Melenhorst JJ; Milone MC
Cancer Immunol Res; 2018 Sep; 6(9):1100-1109. PubMed ID: 30030295
[TBL] [Abstract][Full Text] [Related]
46. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
47. Aging-dependent DNA hypermethylation and gene expression of GSTM1 involved in T cell differentiation.
Yeh SH; Liu CL; Chang RC; Wu CC; Lin CH; Yang KD
Oncotarget; 2017 Jul; 8(30):48591-48602. PubMed ID: 28596482
[TBL] [Abstract][Full Text] [Related]
48. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
49. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
[TBL] [Abstract][Full Text] [Related]
50. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
51. Chimeric antigen receptor T-cells for B-cell malignancies.
Lichtman EI; Dotti G
Transl Res; 2017 Sep; 187():59-82. PubMed ID: 28719798
[TBL] [Abstract][Full Text] [Related]
52. Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry.
Maldini CR; Love AC; Tosh KW; Chan LL; Gayout K; Smith T; Riley JL
J Immunol Methods; 2020; 484-485():112830. PubMed ID: 32745474
[TBL] [Abstract][Full Text] [Related]
53. Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer.
Lopez E; Hidalgo S; Roa E; Gómez J; Hermansen Truan C; Sanders E; Carrasco C; Pacheco R; Salazar-Onfray F; Varas-Godoy M; Borgna V; Lladser A
Oncoimmunology; 2023; 12(1):2225291. PubMed ID: 37363103
[TBL] [Abstract][Full Text] [Related]
54. Persistent STAT5 activation reprograms the epigenetic landscape in CD4
Ding ZC; Shi H; Aboelella NS; Fesenkova K; Park EJ; Liu Z; Pei L; Li J; McIndoe RA; Xu H; Piazza GA; Blazar BR; Munn DH; Zhou G
Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33127608
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics.
Gorovits B; Koren E
BioDrugs; 2019 Jun; 33(3):275-284. PubMed ID: 31069709
[TBL] [Abstract][Full Text] [Related]
56. Rapid manufacturing of non-activated potent CAR T cells.
Ghassemi S; Durgin JS; Nunez-Cruz S; Patel J; Leferovich J; Pinzone M; Shen F; Cummins KD; Plesa G; Cantu VA; Reddy S; Bushman FD; Gill SI; O'Doherty U; O'Connor RS; Milone MC
Nat Biomed Eng; 2022 Feb; 6(2):118-128. PubMed ID: 35190680
[TBL] [Abstract][Full Text] [Related]
57. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies.
Matsueda S; Chodon T; Koya RC
Adv Exp Med Biol; 2019; 1143():217-229. PubMed ID: 31338822
[TBL] [Abstract][Full Text] [Related]
58. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
59. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
60. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
